Pancreatic Surgery Practice Questions

Q: Which of the following conditions does not typically result in an increased serum amylase level?

Acute appendicitis. ***Acute appendicitis*** - While appendicitis can cause abdominal pain, it generally does not involve the pancreas or salivary glands, hence **serum amylase** levels typically remain normal [2]. - The primary inflammatory process in appendicitis is localized to the **appendix**, which does not produce amylase [2]. *Intestinal obstruction* - An intestinal obstruction can lead to **pancreatic irritation** or secondary pancreatitis due to distension and increased intraluminal pressure, resulting in elevated amylase. - Furthermore, **intestinal ischemia** or necrosis can release amylase into the bloodstream. *Perforated ulcer* - A perforated ulcer (especially duodenal) can cause irritation or inflammation of the adjacent **pancreas**, leading to elevated serum amylase [1]. - The leakage of **gastrointestinal contents** into the peritoneal cavity can trigger a chemical peritonitis that may secondarily affect the pancreas. *Acute pancreatitis* - **Acute pancreatitis** directly involves inflammation of the pancreas, the primary organ responsible for producing amylase [3]. - Damaged pancreatic cells release large amounts of **amylase** into the bloodstream, making it a classic marker for this condition [3].

Q: What are the indications for surgical intervention in a patient with pancreatic ascites?

Persistent leak from a stented duct. **Persistent leak from a stented duct** - This indicates that **endoscopic drainage** or stenting has failed to resolve the pancreatic duct leak, requiring a more definitive surgical approach. - **Ongoing leakage** despite internal drainage attempts suggests a persistent anatomical disruption that only surgery can effectively repair. *Persistent symptoms despite medical management* - While persistent symptoms warrant further intervention, this option is too broad and does not specifically point to the failure of less invasive procedures like endoscopic stenting. - Symptoms alone, without evidence of a failed specific intervention, might lead to other non-surgical interventions first. *Initial leak from stented duct* - An initial leak is often managed with **endoscopic stent placement** as the primary, less invasive intervention. - Surgical intervention is typically reserved for cases where initial stenting and conservative measures fail. *Recurrent ascites after drainage with ongoing symptoms* - **Recurrent ascites** after simple drainage (paracentesis) only suggests a persistent leak, but this option does not mention the failure of a stented duct. - The next step after drainage would likely be **endoscopic retrograde cholangiopancreatography (ERCP)** and stenting before considering surgery.

Q: What is the most appropriate treatment plan for a patient diagnosed with a benign insulinoma?

Enucleation. ***Enucleation*** - For **benign solitary insulinomas**, surgical **enucleation** (removal of the tumor while preserving the healthy pancreatic tissue) is the treatment of choice, offering a high cure rate. - This minimally invasive approach minimizes morbidity compared to more extensive pancreatic resections, especially for tumors located superficially or within the pancreatic head. *Enucleation with radiotherapy* - While **enucleation** is the primary treatment for benign insulinomas, **radiotherapy** is generally not indicated as an adjuvant therapy for these benign lesions. - Radiotherapy is more commonly considered for **malignant or unresectable pancreatic neuroendocrine tumors** or for palliative control of symptoms. *Whipple's operation* - A **Whipple's operation (pancreaticoduodenectomy)** is a major surgical procedure typically reserved for tumors in the head of the pancreas that are **malignant or complex**, or for larger benign tumors that cannot be safely enucleated. - For a benign insulinoma that can be enucleated, a Whipple's operation is **overly aggressive** given its high risk of complications and mortality. *Administration of streptozotocin* - **Streptozotocin** is an **antineoplastic agent** that targets pancreatic beta cells and is primarily used for **malignant, metastatic, or unresectable insulinomas** to control symptoms and tumor growth. - It is not an appropriate first-line treatment for a **benign, resectable insulinoma**, as surgical removal is curative.

Q: What is the median survival time for patients with carcinoma of the pancreas after surgery and adjuvant therapy?

Approximately 22 months. ***Approximately 22 months*** - The median survival for patients with **resectable pancreatic adenocarcinoma** treated with surgery (typically pancreaticoduodenectomy) and adjuvant chemotherapy is approximately **22-28 months** based on contemporary studies. - The 22-month figure represents a well-established median from multiple clinical trials including **ESPAC-1 and CONKO-001**, making it the most representative answer among the options provided. - This outcome reflects significant improvement from the pre-adjuvant therapy era but still underscores the aggressive biology of pancreatic cancer. *Approximately 12 months* - This figure represents **historical median survival** prior to the routine use of effective adjuvant chemotherapy, or survival in patients with **unresectable locally advanced disease** treated with palliative chemotherapy alone. - It is **not representative** of outcomes in patients who undergo complete surgical resection followed by modern adjuvant therapy. *Approximately 32 months* - While highly selected patients with **favorable tumor biology** (small tumors, negative margins, low CA 19-9) and optimal response to modern regimens like **FOLFIRINOX** may approach this survival, it exceeds the **median survival** for the general population of resected patients. - This represents the upper quartile rather than the median outcome. *Approximately 44 months* - This exceptionally long survival is **not achieved** as a median in pancreatic ductal adenocarcinoma, even with optimal surgical resection and adjuvant therapy. - Such prolonged survival is occasionally seen in **highly selected patients** or with less aggressive pancreatic neoplasms (e.g., neuroendocrine tumors, intraductal papillary mucinous neoplasms with invasive component), which have substantially better prognoses than typical ductal adenocarcinoma.

Q: Treatment of choice for annular pancreas is

Duodeno duodenostomy. ***Duodeno duodenostomy*** - This procedure **bypasses the annular segment** of the pancreas by creating an anastomosis between the two healthy segments of the duodenum, proximal and distal to the obstruction. - It maintains the continuity of the **gastrointestinal tract** and preserves pancreatic and biliary outflow into the duodenum. *Gastrojejunostomy* - This procedure connects the stomach to the jejunum, **bypassing the duodenum entirely**. - While it can relieve gastric outlet obstruction, it does not directly address the **duodenal obstruction** caused by an annular pancreas and can lead to **biliary stasis** and malabsorption due to bypassing the duodenal papilla. *Vagotomy and GJ* - **Vagotomy** is a procedure to reduce acid secretion in the stomach, typically performed for peptic ulcer disease, and is **irrelevant** to the anatomical obstruction of an annular pancreas. - **Gastrojejunostomy** alone, as mentioned, is not the optimal solution for duodenal obstruction caused by an annular pancreas as it bypasses an important digestive segment. *Billroth 2 reconstruction* - This is a type of **gastrectomy** where the stomach is resected and the remainder is anastomosed to the jejunum. - It is used for conditions like gastric cancer or complicated ulcers and is **not indicated** for an annular pancreas, which primarily causes duodenal obstruction.

Q: Which of the following is the LEAST likely indication for surgical intervention in pancreatic ascites?

Persistent symptoms despite conservative management. ***Persistent symptoms despite conservative management*** - This is the **LEAST likely indication** because it is vague and non-specific compared to the other options - Conservative management for pancreatic ascites (including bowel rest, TPN, somatostatin analogues) typically requires **4-6 weeks to assess efficacy** - "Persistent symptoms" alone does not constitute a surgical indication unless accompanied by **specific complications** or **documented failure** of conservative therapy - Surgery is considered only after clear evidence of treatment failure, not merely symptom persistence during the trial period *Recurrent ascites with significant symptoms* - **Recurrence of ascites** after initial control indicates failure of conservative or endoscopic management - Significant symptoms (abdominal distension, pain, respiratory compromise, malnutrition) with recurrence are a **strong indication for surgical intervention** - Suggests underlying pancreatic duct disruption that requires definitive surgical repair *Failure of medical management* - **Clear failure of medical management** is a **primary indication for surgery** in pancreatic ascites - Includes failure to control ascites with octreotide, TPN, repeated paracentesis, and bowel rest - Indicates need for surgical approaches such as internal drainage, resection, or duct repair *Leak from the stented duct* - A **leak from a stented pancreatic duct** represents **failure of endoscopic therapy** - This is a **direct and specific indication** for surgical intervention - Ongoing pancreatic fluid leakage despite stenting requires surgical repair to prevent complications such as infection, malnutrition, and persistent fluid collections

Question 1

Which of the following conditions does not typically result in an increased serum amylase level?

Accepted Answer

Acute appendicitis

Answer

Perforated ulcer

Answer

Acute pancreatitis

Answer

Intestinal obstruction

Question 2

What are the indications for surgical intervention in a patient with pancreatic ascites?

Accepted Answer

Persistent leak from a stented duct

Answer

Initial leak from stented duct

Answer

Persistent symptoms despite medical management

Answer

Recurrent ascites after drainage with ongoing symptoms

Question 3

What is the most appropriate treatment plan for a patient diagnosed with a benign insulinoma?

Accepted Answer

Enucleation

Answer

Enucleation with radiotherapy

Answer

Whipple's operation

Answer

Administration of streptozotocin

Question 4

What is the median survival time for patients with carcinoma of the pancreas after surgery and adjuvant therapy?

Accepted Answer

Approximately 22 months

Answer

Approximately 12 months

Answer

Approximately 32 months

Answer

Approximately 44 months

Question 5

Treatment of choice for annular pancreas is

Accepted Answer

Duodeno duodenostomy

Answer

Vagotomy and GJ

Answer

Billroth 2 reconstruction

Answer

Gastrojejunostomy

Question 6

Which of the following is the LEAST likely indication for surgical intervention in pancreatic ascites?

Accepted Answer

Persistent symptoms despite conservative management

Answer

Recurrent ascites with significant symptoms

Answer

Failure of medical management

Answer

Leak from the stented duct

Pancreatic Surgery — MCQs

Pancreatic Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?